Biosense, established in 1994, developed a Cardiac Electrophysiology Mapping and Ablation System. The system includes an electromagnetic micro-catheter and a locating system positioned outside the patientís body. Biosenseís system is the first effective form of treatment for the most common cardiac rhythm disturbance, called ventricular tachycardia (VT). The system treats the cardiac disturbance by accurately tracing, and then ablating, the small lesion, which causes VT. In October 1997, the company was acquired by Johnson & Johnson (NYSE: JNJ).
    Status: Second round  
    Fund I  
    Email Biosense  
    Haetgar 7, P.O.Box 2009, Tirat Hacarmel 39120  
    Jim Dennis, CEO  
    Founded 1994  

Neomedia - Keepin' it simple!